KOHL CHEVRIER: Open Payments
NPI 1619671369 · HAMBURG, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,773 in 132 payments from 25 companies in 2025. Trend: 2023 $1,558 · 2024 $2,617 · 2025 $2,773
Food & beverage: $2,773
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $349 |
| PFIZER INC. | 16 | $318 |
| AstraZeneca Pharmaceuticals LP | 9 | $311 |
| GlaxoSmithKline, LLC. | 13 | $257 |
| Lilly USA, LLC | 11 | $215 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $191 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $166 |
| Amgen Inc. | 7 | $115 |
| Exact Sciences Corporation | 5 | $105 |
| ABBVIE INC. | 4 | $90 |
Products named: TRELEGY ELLIPTA, CAPLYTA, AIRSUPRA, Ozempic, XIFAXAN, MOUNJARO, JARDIANCE, NURTEC ODT.
Industry payments across NY — which companies pay providers there.
